A follow-up study has revealed physical interaction between GFI1 and LSD1 for tumorigenesis, identifying an LSD1 inhibitor as a new potential therapeutic drug for GFI1/MYC-driven MB (88) Thus, understanding of the mechanisms underlying abnormal enhancer activities within cancer genomes leads to the discovery of novel therapeutic targets. Here, KDM1A is linked to cancer.